Minimally Invasive Devices, Inc. (MID), a Columbus, Ohio-based developer of a device that prevents loss of vision during laparoscopic surgery, completed a $9m Series B financing.
The round was led by Canaan Partners, with participation from existing investor Charter Life Science. In conjunction with the funding, Brent Ahrens, general partner at Canaan Partners, has been appointed to the board of directors. Jim Bobbitt, former vice president of sales and marketing for Neomend, Inc., has been appointed vice president of sales.
The company intends to use the capital to establish a direct sales unit, expand manufacturing operations, develop complimentary products and generate additional data to support the efficacy of their system.
Led by Wayne Poll, M.D., founder and CEO, Minimally Invasive Devices has developed and manufactures the FDA-approved FloShield™ laparoscopic vision system, which prevents loss of vision during laparoscopic surgery due to obscuration of the optics by attaching to the HD camera system and using an air curtain to form an invisible protective barrier over the lens.
The system is augmented by the Flo-X lens wash, a biocompatible surfactant that will flush the lens inside the body if needed, so that surgeons may operate without loss of vision and without lens removal.